VEGF、HIF-1α与上皮性卵巢癌血管生成及生物学行为的关系

中华养生保健 ›› 2023, Vol. 41 ›› Issue (20): 10-13.

VEGF、HIF-1α与上皮性卵巢癌血管生成及生物学行为的关系

王稳¹, 马军霞², 崔秀娟¹, 田翔宇^3,*

1.滕州市中心人民医院妇产科,山东枣庄,277599;
2.滕州市中心人民医院计生办,山东枣庄,277599;
3.滕州市中心人民医院医学影像中心,山东枣庄,277599

出版日期:2023-10-16 发布日期:2023-10-12
通讯作者: ^*田翔宇,E-mail：tianxiangyu1984@163.com。
作者简介:王稳（1984—）,女,汉族,籍贯：山东省枣庄市,博士研究生,主治医师,研究方向：妇科肿瘤。
基金资助:
徐州医科大学附属医院发展基金《VEGF、HIF-1α与上皮性卵巢癌血管生成及生物学行为的关系》（XYFY2020055）; 滕州市中心人民医院“扬帆”计划《高分辨MRI联合经阴道超声在深部浸润型子宫内膜异位症中的诊断价值》（202306）

VEGF, HIF-1 α The Relationship between Angiogenesis and Biological Behavior in Epithelial Ovarian Cancer

WANG Wen¹, MA Jun-xia², CUI Xiu-juan¹, TIAN Xiang-yu^3,*

1. Obstetrics and Gynecology Department of Tengzhou Central People's Hospital, Zaozhang Shandong 277599, China;
2. Family Planning Office of Tengzhou Central People's Hospital, Zaozhang Shandong 277599, China;
3. Medical Imaging Center of Tengzhou Central People's Hospital, Zaozhang Shandong 277599, China

Online:2023-10-16 Published:2023-10-12

摘要/Abstract

摘要： 目的探讨上皮性卵巢癌与正常卵巢组织中血管内皮生长因子、缺氧诱导因子-1α以及微血管密度的表达及其与预后的关系。方法回顾性分析滕州市中心人民医院收治的46例EOC患者的临床资料,探讨其临床病理特征与VEGF、HIF-1α以及MVD表达的关系。应用免疫组织化学的方法测定EOC和正常卵巢组织中VEGF、HIF-1α的表达,应用CD34评估新生血管的MVD。VEGF、HIF-1α以及MVD的表达与总生存期的关系采用Kaplan-Meier生存曲线。结果 EOC患者肿瘤组织中VEGF、HIF-1α和MVD的表达与FIGO分期、病理学分级和有无淋巴结转移有关,差异有统计学意义（P<0.05）,与年龄、组织学亚型无关（P>0.05）。VEGF、HIF-1α和MVD的表达在EOC组织中的表达明显高于正常卵巢组织,差异有统计学意义（P<0.05）。VEGF、HIF-1α和MVD高表达组的EOC患者总生存期更短,差异有统计学意义（P<0.05）。结论血管生成与EOC的生长、转移和预后有着密切关系,VEGF和MVD的表达可作为反映EOC血管生成的指标。在肿瘤血管的生成、进展、转移等过程中,缺氧微环境均发挥着重要作用,VEGF以及HIF-1α等肿瘤生长依赖的因子有望成为肿瘤治疗的新靶点,肿瘤晚期患者的预后有望通过分子免疫学治疗得到改善。

关键词: 血管内皮生长因子, 血管生成, 缺氧诱导因子-1α, 上皮性卵巢癌

Abstract: Objective To detect the expression of VEGF, HIF-1α and MVD in EOC and normal ovarian tissues and their relationship with prognosis. Methods The clinical data of 46 EOC patients were retrospectively analyzed to investigate the relationship between the clinicopathological characteristics and the expression of VEGF, HIF-1α and MVD. Immunohistochemistry was performed to measure VEGF, HIF-1α expression in normal ovarian tissues and EOCs,and MVD was determined by using immunostaining of CD34. The survival analysis was performed by using Kaplan-Meier method to determine whether the expression of VEGF, HIF-1α and MVD was associated with the overall survival of EOC patients. Results The expression of VEGF, HIF-1α and MVD in EOC tissues were correlated with FIGO stage, pathological grade and lymph node metastasis(P<0.05), but not with age or histological subtype（P>0.05）. The expressions of VEGF, HIF-1α and MVD in EOC tissues were significantly higher than those in normal ovarian tissues(P<0.05). The overall survival probability of high group of VEGF, HIF-1α and MVD was significantly lower than those of the low group(P<0.05). Conclusion Angiogenesis is closely related to the growth, metastasis and prognosis of EOC, and the expression of VEGF and MVD can be used as indicators of EOC angiogenesis. Hypoxic microenvironment plays an important role in the process of tumor angiogenesis, progression and metastasis. Tumor growth-dependent factors such as VEGF and HIF-1α are expected to become new targets for tumor therapy. Molecular biological targeted therapy targeting HIF-1α or hypoxic microenvironment may bring new hope for the treatment of advanced malignant tumors and thereby improve the prognosis of patients.

Key words: VEGF, angiogenesis, HIF-1α, epithelial ovarian cancer

中图分类号:

R711.75

王稳, 马军霞, 崔秀娟, 田翔宇. VEGF、HIF-1α与上皮性卵巢癌血管生成及生物学行为的关系[J]. 中华养生保健, 2023, 41(20): 10-13.

WANG Wen, MA Jun-xia, CUI Xiu-juan, TIAN Xiang-yu. VEGF, HIF-1 α The Relationship between Angiogenesis and Biological Behavior in Epithelial Ovarian Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(20): 10-13.

参考文献

[1] MURPHY A D, MORGAN R D, CLAMP A R, et al.The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer[J]. Br J Cancer,2022,126(6):851-864.
[2] RÜEGG C, DORMOND O, MARIOTTI A. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis[J]. Biochim Biophys Acta,2004,1654(1):51-67.
[3] WANG X, DU Z W, XU T M, et al.HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies[J]. Front Oncol,2021,11:785111.
[4] LIM D, DO Y, KWON B S, et al.Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer[J]. BMB Rep,2020,53(6):291-298.
[5] WANG Y, LI B X, LI X.Identification and Validation of Angiogenesis-Related Gene Expression for Predicting Prognosis in Patients With Ovarian Cancer[J]. Front Oncol,2022,11:783666.
[6] YOU L, WU W, WANG X, et al .The role of hypoxia-inducible factor 1 in tumor immune evasion[J]. Med Res Rev,2021,41(3): 1622-1643.
[7] KURMAN R J, CARCANGIU M L, HERRINGTON C S, et al. WHO Classilication of Tumours of Female Reproductive Organs[M].2014, 4th edition, International Agency for Research on Cancer (IARC).
[8] SUN J, SHA B, ZHOU W, et al.VEGF-mediated angiogenesis stimulates neural stem cell proliferation and differentiation in the premature brain[J]. Biochem Biophys Res Commun,2010,394(1):146-152.
[9] TANG H S,FENG Y J,YAO L Q.Angiogenesis, vasculogenesis, andvasculogenic mimicry in ovarian cancer[J]. International Journal ofGynecological Cancer,2009,19(4):605-610.
[10] PE'ER J, SHWEIKI D, LTIN A, et al. Hypoxia-induced expression of vascular endo-thelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases[J]. Lab Invest,1995,72(6):638-645.
[11] SILINS G, GRIMMOND S, EGERTON M, et al.Analysis of the promoter region of the human VEGF-related factor gene[J]. Biochem Biophys Res Commun,1997, 230(2):413-418.
[12] FORSYTHE J A, JIANG B H, LYER N V, et al.Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1[J]. Mol Cell Biol,1996,16(9):4604-4613.
[13] MANIOTIS A J, FOLBERG R, HESS A, et al.Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol,1999,155(3):739-752.
[14] FAN Y, CHENG H, LIU Y, et al.Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells[J]. Front Pharmacol,2022,13:955984.
[15] OLALEKAN S, XIE B, BACK R, et al.Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics[J]. Cell Rep,2021,35(8):109165.
[16] ZHANG Q L, DING J S, WANG Y M, et al.Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review)[J]. Oncol Rep,2022,47(5):102.
[17] Almeida-Nunes DL, Mendes-Frias AM, Silvestre R, et al.Immune Tumor Microenvironment in Ovarian Cancer Ascites[J]. Int J Mol Sci,2022,23(18):10692.
[18] SALINAS-VERA Y M, GALLARDO-RINCÓN D, RUÍZ-GARCÍA E, et al. The Role of Hypoxia in Endometrial Cancer[J]. Curr Pharm Biotechnol,2022,23(2):221-234.
[19] KLEMBA A, BODNAR L, WAS H, et al.Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo-and Immunotherapies[J]. Int J Mol Sci,2020,21(24):9492.